BCL2 and cancer: The target genes were significantly enriched in 153 KEGG pathways, such as the p53 signaling pathway (hsa04115; genes: Tumor Protein53 (TP53), BAX, Cyclin-Dependent Kinase Inhibitor1A (CDKN1A), etc.), Forkhead Box O (FoxO) signaling pathway (hsa04068; genes: AKT1, CDKN1A, SIRT1, etc.), Adenosine 5'-monophosphate (AMP)-Activated Protein Kinase (AMPK) signaling pathway (hsa04152; genes: AKT1, Mechanistic Target of Rapamycin (mTOR), SIRT1), longevity regulating pathway (hsa04211; genes: AKT1, BAX, SIRT1, etc.), and microRNAs in cancer (hsa05206: genes: BCL2, CDKN1A, SIRT1, etc.).